SynthesisRMD open2026
Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature review.
Synthesis in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe Assessment of SpondyloArthritis International Society-Spondyloarthritis and Peripheral Arthritis Disease Activity Instrument Selection and Evaluation (ASAS-SPARADISE) project aims to identify instruments to assess disease activity due to peripheral arthritis in axial (axSpA) and peripheral spondyloarthritis (pSpA). We aimed to summarise and compare the measurement properties of instruments used for this purpose as part of the ASAS-SPARADISE.
methodsA systematic literature review (Medline/EMBASE/Cochrane; until February 2025) was conducted following the Population-Instrument-Measurement framework. Eligible studies included adults with axSpA or pSpA and peripheral arthritis. Instruments retained from a previous review, after domain-match and feasibility assessment, included: Patient Global Assessment (PGA), swollen joint count (66/44), tender joint count (68/44), C reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Axial Spondyloarthritis Disease Activity Score (ASDAS), Disease Activity Index for Psoriatic Arthritis (DAPSA) and Disease Activity Score using 44 joints. Measurement properties evaluated were construct validity (correlation hypotheses; known-groups discrimination) and discrimination (test-retest reliability, responsiveness; clinical trial discrimination; thresholds of meaning). Risk of bias was assessed using the Outcome Measures on Rheumatology (OMERACT) Good Methods Checklist and evidence was synthesised following OMERACT rules (GREEN-good; AMBER-adequate; RED-poor performance).
resultsOf 4,364 records screened, eight studies were eligible. Evidence in axSpA was limited to PGA, CRP and BASDAI, rating mostly AMBER for construct validity, longitudinal construct validity and discrimination in clinical trials. In pSpA, composite instruments showed better results, with BASDAI, ASDAS and DAPSA rating mostly GREEN. No study provided test-retest reliability or thresholds of meaning.
conclusionsEvidence supporting instruments to assess peripheral arthritis in spondyloarthritis remains scarce, especially in axSpA. Composite instruments in pSpA performed better, but evidence gaps persist, highlighting the need for validated, domain-specific instruments. PROSPERO REGISTRATION NUMBER: CRD420251177596.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.